文献速递炎症性肠病

抗生素使用差异影响IBD患者抗TNF治疗中抗药抗体形成风险

Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN.
PubMed 文献 · Gut · 2021-08-03

基于以色列全国IBD登记库(epi-IIRN)1946例抗TNF治疗患者的数据,中位随访651天,363例出现抗药抗体(ADA)。头孢菌素和青霉素-β内酰胺酶抑制剂增加ADA风险,而大环内酯类和氟喹诺酮类降低风险;小鼠实验支持微生物组成影响ADA产生。

要点

  • 头孢菌素类抗生素增加抗TNF治疗中ADA形成风险(HR=1.97)。
  • 青霉素-β内酰胺酶抑制剂也增加ADA风险(HR=1.4)。
  • 大环内酯类和氟喹诺酮类可能降低ADA风险。

核心结论

  • ADA产生与肠道微生物组成相关,避免头孢菌素和青霉素-BLIs或使用氟喹诺酮类/大环内酯类可能降低抗TNF治疗中ADA风险。

研究设计与样本

  • 基于以色列全国IBD登记库(epi-IIRN)的队列分析,纳入1946例接受抗TNF治疗且可获取ADA水平的患者。
  • 使用时变协变量的生存分析评估抗生素使用与ADA发展的关联。
  • 另用特定病原菌和无菌C57BL小鼠进行抗生素预处理后英夫利西单抗攻击实验,14天后评估ADA。

主要发现

  • 中位随访651天,1946例中363例出现阳性ADA。
  • 头孢菌素类使用与ADA风险增加相关(HR=1.97,95%CI 1.58-2.44)。
  • 青霉素-β内酰胺酶抑制剂使用与ADA风险增加相关(HR=1.4,95%CI 1.13-1.74)。
  • 大环内酯类使用与ADA风险降低相关(HR=0.38,95%CI 0.16-0.86)。
  • 氟喹诺酮类使用与ADA风险降低相关(HR=0.20,95%CI 0.12-0.35)。

关键数值与推荐

  • 头孢菌素类HR=1.97(95%CI 1.58-2.44),青霉素-BLIs HR=1.4(95%CI 1.13-1.74),大环内酯类HR=0.38(95%CI 0.16-0.86),氟喹诺酮类HR=0.20(95%CI 0.12-0.35)。
  • 小鼠实验中,头孢菌素预处理组ADA产生显著高于大环内酯预处理组;无菌小鼠不产生ADA。

临床怎么用

  • 临床对抗TNF治疗的IBD患者处方抗生素时,可优先考虑氟喹诺酮类或大环内酯类而非头孢菌素或青霉素-BLIs,以降低ADA形成风险。

局限性

  • 观察性登记数据可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Anti-drug antibodies (ADA) to anti-tumour necrosis factor (anti-TNF) therapy drive treatment loss of response. An association between intestinal microbial composition and response to anti-TNF therapy was noted. We therefore aimed to assess the implications of antibiotic treatments on ADA formation in patients with inflammatory bowel disease (IBD). DESIGN: We analysed data from the epi-IIRN (epidemiology group of the Israeli IBD research nucleus), a nationwide registry of all patients with IBD in Israel. We included all patients treated with anti-TNF who had available ADA levels. Survival analysis with drug use as time varying covariates were used to assess the association between antibiotic use and ADA development. Next, specific pathogen and germ-free C57BL mice were treated with respective antibiotics and challenged with infliximab. ADA were assessed after 14 days. RESULTS: Among 1946 eligible patients, with a median follow-up of 651 days from initiation of therapy, 363 had positive ADA. Cox proportional hazard model demonstrated an increased risk of ADA development in patients who used cephalosporins (HR=1.97, 95% CI 1.58 to 2.44), or penicillins with β-lactamase inhibitors (penicillin-BLI, HR=1.4, 95% CI 1.13 to 1.74), whereas a reduced risk was noted in patients treated with macrolides (HR=0.38, 95% CI 0.16 to 0.86) or fluoroquinolones (HR=0.20, 95% CI 0.12 to 0.35). In mice exposed to infliximab, significantly increased ADA production was observed in cephalosporin as compared with macrolide pretreated mice. Germ-free mice produced no ADA. CONCLUSION: ADA production is associated with the microbial composition. The risk of ADA development during anti-TNF therapy can possibly be reduced by avoidance of cephalosporins and penicillin-BLIs, or by treatment with fluoroquinolones or macrolides.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Gorelik Y, Freilich S, Gerassy-Vainberg S, et al. Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN. Gut. 2021. PMID: 34344783. doi:10.1136/gutjnl-2021-325185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。